Project description:Constipation affects approximately 15% of the global population, and gut microbiota dysbiosis is implicated in its pathogenesis. Rothia mucilaginosa, a commensal bacterium with established anti-inflammatory properties, has not been previously investigated for its effects on intestinal function. In this study, we evaluated the therapeutic potential of R. mucilaginosa in a loperamide-induced constipation mouse model using multiomics approaches. Twenty-six SPF male C57BL/6 mice were divided into normal control (NC, n=8), constipation model control (MC, n=8), and R. mucilaginosa-treated (RG, n=10) groups. R. mucilaginosa intervention significantly improved fecal output and induced gut microbiota remodeling, including enrichment of Akkermansia muciniphila and Alistipes finegoldii. To characterize host molecular responses, RNA-seq was performed on colon tissues to identify differentially expressed genes and pathways associated with constipation alleviation, with particular focus on neuroactive pathway activation.
Project description:<p>Untargeted metabolomics was performed on colon tissue from 26 C57BL/6 mice to investigate metabolic mechanisms underlying Rothia mucilaginosa-mediated constipation alleviation. Mice were divided into normal control (NC, n=8), loperamide-induced constipation model control (MC, n=8), and R. mucilaginosa gavage-treated (RG, n=10) groups. The experimental protocol consisted of adaptation (days 0-7), loperamide modeling (days 8-21), and R. mucilaginosa intervention (days 22-40, BNCC363031, 2x10^8 CFU/day). Colon tissue metabolomics was performed using UHPLC-MS/MS (Vanquish UHPLC coupled with Orbitrap Exploris 120, Thermo Fisher) in both positive and negative ionization modes. This dataset supports the identification of differential metabolites and metabolic pathways associated with R. mucilaginosa intervention in constipation, with particular focus on tryptophan metabolism, bile acid metabolism, and neuroactive signaling.</p>
